The association of immunity with enhanced class II and costimulatory molecule expression and in vitro activation of antigen-specific CD4+ T cells by TSA-treated melanoma cells is consistent with the hypothesis of direct antigen presentation by tumor cells in vivo. Here, CD4 is linked to melanoma.